Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 11/20 | 0.50 |
| ▸ | ACACB | O00763 | 3/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298279 | 0.83 | SCN9A (0.50) | SCN9AACACBLIPGPDE4DHTR2A | |
| SCHEMBL2303113 | 0.74 | SCN9A (0.49) | SCN9AACACBHTR2AHTR2CHTR2B | |
| SCHEMBL2299566 | 0.73 | SCN9A (0.53) | SCN9AACACBLIPG | |
| SCHEMBL6379561 | 0.71 | GRIN2B (0.49) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL17610091 | 0.71 | GRIN2B (0.49) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL17609959 | 0.70 | GRIN2B (0.45) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21130412 | 0.67 | PDE4D (0.44) | SCN9AACACBLIPGPDE4DHTR2A | |
| SCHEMBL6375908 | 0.67 | GRIN2B (0.45) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7394734 | 0.67 | PRKCQ (0.48) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2722843 | 0.67 | ALDH1A1 (0.48) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | SCN9A 18/4885ACACB 1915/4885LIPG 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.